Medical Marijuana Inc (MJNA)

[Art Vandeley]

Theravalues Corporation – International Joint Venture
On April 10, 2014, Kannalife™ entered into a Memorandum of Understanding (the “Theravalues
MOU”) with Theravalues Corporation, a Japanese pharmaceutical company specializing in antioxidative
stress relieving nutraceuticals and pharmaceuticals (“Theravalues”).
The Theravalues MOU describes the potential terms of an eventual joint venture and/or a
Revenue Sharing Agreement and/or and Materials Supply and Transfer Agreement to further
their mutual efforts to commercialize high quality, phyto-botanical, semi-synthetic and synthetic
pharmaceutical grade products from botanicals in North America and Japan.
The areas of focus for the proposed joint venture revolve around the joint research and
development of combination therapeutics using naturopathic (plant based) and synthetic
(pharmaceutical grade) compounds consisting of Theracurmin® (high absorption Curcurmin);
EMIQ™ (high absorption Quercetin); KLS-13019 (a novel synthetic benzo-diol); Traumatol™;
KannaHops™ and other naturally derived cannabinoids on a worldwide basis.
Under the terms of the proposed agreement, Theravalues would sell to the company, at a to-benegotiated
price, not to exceed the lowest wholesale price paid by any Theravalues customer,
bulk quantities of Theracurmin® (high absorption Curcurmin); and EMIQ™ (high absorption
Quercetin), for the Company’s use and purpose of creating new products based on cannabinoid
related combination Phytoextract Medicaments and Naturopathic products for sale through
Kanna Botanicals, Inc. (a wholly owned subsidiary of the company). Such products would
include, but not be limited to, ingestible tablets; oral sprays; skin patches; liquid tinctures and
extracts; edibles; skin care products and hair care products.
The sale of bulk quantities of Theracurmin® (high absorption Curcurmin); and EMIQ™ (high
absorption Quercetin) to the Company by Theravalues would be on an exclusive basis to KLSI
for cannabinoid based Combination Phytoextract Medicaments and Naturopathic Products, and
shall not endeavor to sell bulk quantities of Theracurmin® (high absorption Curcurmin); and
EMIQ™ (high absorption Quercetin) to any third party seeking to use TVC’s products in
combination with cannabinoid based products.
As part of the Theravalues MOU, the company may employ the direct sales and marketing
efforts of its network sales channel Kannaway™ LLC. Regarding intellectual property,
Theravalues and the Company shall have joint patent ownership on novel combination synthetic
therapeutics involving synthesized Theracurmin® and KLS-13019, worldwide.